STLN

SEC source: 0001628280-22-026163 · wf-form4_166517567146567.xml · derivative · entry 7

BARASCH RICHARD A · CIK 0001076341 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 548,503

Underlying: Common stock · 548,503 shares

Expires not disclosed

F5 · security: Each whole private placement warrant (the "Private Placement Warrant") entitles the holder thereof to purchase one share of the issuer's common stock at an exercise price of $11.50 per share. The warrants are currently exercisable and will expire on November 12, 2026 or earlier upon redemption or liquidation.

F5 · derivative.exercise_price: Each whole private placement warrant (the "Private Placement Warrant") entitles the holder thereof to purchase one share of the issuer's common stock at an exercise price of $11.50 per share. The warrants are currently exercisable and will expire on November 12, 2026 or earlier upon redemption or liquidation.

F1 · kind: Represents securities received in distributions to LLC members, on a pro rata basis for no consideration, in exempt transactions under Rule 16a-9.

F1 · price: Represents securities received in distributions to LLC members, on a pro rata basis for no consideration, in exempt transactions under Rule 16a-9.

F5 · derivative.exercise_date: Each whole private placement warrant (the "Private Placement Warrant") entitles the holder thereof to purchase one share of the issuer's common stock at an exercise price of $11.50 per share. The warrants are currently exercisable and will expire on November 12, 2026 or earlier upon redemption or liquidation.

F5 · derivative.expiration_date: Each whole private placement warrant (the "Private Placement Warrant") entitles the holder thereof to purchase one share of the issuer's common stock at an exercise price of $11.50 per share. The warrants are currently exercisable and will expire on November 12, 2026 or earlier upon redemption or liquidation.

SEC source: 0001628280-22-026163 · wf-form4_166517567146567.xml · derivative · entry 6

BARASCH RICHARD A · CIK 0001076341 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Family Trust

Disclosed balance after: 894

Underlying: Common stock · 89,400 shares

Expires not disclosed

F4 · security: Represents shares of Common Equivalent Preferred Stock held in escrow, (i) 50% of which shall be released from escrow in the event the issuer's stock price equals or exceeds $12.50 per share for 20 days within any 30 consecutive trading days during the two-year period ending on November 12, 2023, and (ii) the remainder of which shall be released from escrow in the event the issuer's stock price equals or exceeds $15.00 per share for any 20 trading days within any 30-day trading period during the three-year period ending November 12, 2024. Notwithstanding the forgoing, all shares shall be released from escrow in the event of a qualifying change of control.

F4 · derivative.exercise_price: Represents shares of Common Equivalent Preferred Stock held in escrow, (i) 50% of which shall be released from escrow in the event the issuer's stock price equals or exceeds $12.50 per share for 20 days within any 30 consecutive trading days during the two-year period ending on November 12, 2023, and (ii) the remainder of which shall be released from escrow in the event the issuer's stock price equals or exceeds $15.00 per share for any 20 trading days within any 30-day trading period during the three-year period ending November 12, 2024. Notwithstanding the forgoing, all shares shall be released from escrow in the event of a qualifying change of control.

F1 · kind: Represents securities received in distributions to LLC members, on a pro rata basis for no consideration, in exempt transactions under Rule 16a-9.

F1 · price: Represents securities received in distributions to LLC members, on a pro rata basis for no consideration, in exempt transactions under Rule 16a-9.

F4 · derivative.exercise_date: Represents shares of Common Equivalent Preferred Stock held in escrow, (i) 50% of which shall be released from escrow in the event the issuer's stock price equals or exceeds $12.50 per share for 20 days within any 30 consecutive trading days during the two-year period ending on November 12, 2023, and (ii) the remainder of which shall be released from escrow in the event the issuer's stock price equals or exceeds $15.00 per share for any 20 trading days within any 30-day trading period during the three-year period ending November 12, 2024. Notwithstanding the forgoing, all shares shall be released from escrow in the event of a qualifying change of control.

F4 · derivative.expiration_date: Represents shares of Common Equivalent Preferred Stock held in escrow, (i) 50% of which shall be released from escrow in the event the issuer's stock price equals or exceeds $12.50 per share for 20 days within any 30 consecutive trading days during the two-year period ending on November 12, 2023, and (ii) the remainder of which shall be released from escrow in the event the issuer's stock price equals or exceeds $15.00 per share for any 20 trading days within any 30-day trading period during the three-year period ending November 12, 2024. Notwithstanding the forgoing, all shares shall be released from escrow in the event of a qualifying change of control.

F2 · ownership.nature: Securities held by the Helen Barasch Family Trust #1 (the "Trust"), of which the reporting person is the investment manager and has voting and dispositive power over the securities held by the Trust, but disclaims beneficial ownership of these shares except to any pecuniary interest therein.

SEC source: 0001628280-22-026163 · wf-form4_166517567146567.xml · derivative · entry 5

BARASCH RICHARD A · CIK 0001076341 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Family Trust

Disclosed balance after: 6,204

Underlying: Common stock · 620,400 shares

Expires not disclosed

F3 · security: Each share of Series A Common Stock Equivalent Convertible Preferred Stock ("Common Equivalent Preferred Stock") is convertible into 100 shares of common stock (subject to adjustment) at any time and from time to time at the election of the holder thereof. The Common Equivalent Preferred Stock has no expiration date. The terms of the Common Equivalent Preferred Stock restrict the conversion of such shares to the extent that, upon such conversion, the number of shares of Class A Common Stock then beneficially owned by the holder and its affiliates and any other person or entities with which such holder would constitute a Section 13(d) "group" would exceed 4.9% of the total number of shares of Class A Common Stock then outstanding.

F3 · derivative.exercise_price: Each share of Series A Common Stock Equivalent Convertible Preferred Stock ("Common Equivalent Preferred Stock") is convertible into 100 shares of common stock (subject to adjustment) at any time and from time to time at the election of the holder thereof. The Common Equivalent Preferred Stock has no expiration date. The terms of the Common Equivalent Preferred Stock restrict the conversion of such shares to the extent that, upon such conversion, the number of shares of Class A Common Stock then beneficially owned by the holder and its affiliates and any other person or entities with which such holder would constitute a Section 13(d) "group" would exceed 4.9% of the total number of shares of Class A Common Stock then outstanding.

F1 · kind: Represents securities received in distributions to LLC members, on a pro rata basis for no consideration, in exempt transactions under Rule 16a-9.

F1 · price: Represents securities received in distributions to LLC members, on a pro rata basis for no consideration, in exempt transactions under Rule 16a-9.

F3 · derivative.exercise_date: Each share of Series A Common Stock Equivalent Convertible Preferred Stock ("Common Equivalent Preferred Stock") is convertible into 100 shares of common stock (subject to adjustment) at any time and from time to time at the election of the holder thereof. The Common Equivalent Preferred Stock has no expiration date. The terms of the Common Equivalent Preferred Stock restrict the conversion of such shares to the extent that, upon such conversion, the number of shares of Class A Common Stock then beneficially owned by the holder and its affiliates and any other person or entities with which such holder would constitute a Section 13(d) "group" would exceed 4.9% of the total number of shares of Class A Common Stock then outstanding.

F3 · derivative.expiration_date: Each share of Series A Common Stock Equivalent Convertible Preferred Stock ("Common Equivalent Preferred Stock") is convertible into 100 shares of common stock (subject to adjustment) at any time and from time to time at the election of the holder thereof. The Common Equivalent Preferred Stock has no expiration date. The terms of the Common Equivalent Preferred Stock restrict the conversion of such shares to the extent that, upon such conversion, the number of shares of Class A Common Stock then beneficially owned by the holder and its affiliates and any other person or entities with which such holder would constitute a Section 13(d) "group" would exceed 4.9% of the total number of shares of Class A Common Stock then outstanding.

F2 · ownership.nature: Securities held by the Helen Barasch Family Trust #1 (the "Trust"), of which the reporting person is the investment manager and has voting and dispositive power over the securities held by the Trust, but disclaims beneficial ownership of these shares except to any pecuniary interest therein.

SEC source: 0001628280-22-026163 · wf-form4_166517567146567.xml · derivative · entry 4

BARASCH RICHARD A · CIK 0001076341 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 230

Underlying: Common stock · 23,000 shares

Expires not disclosed

F4 · security: Represents shares of Common Equivalent Preferred Stock held in escrow, (i) 50% of which shall be released from escrow in the event the issuer's stock price equals or exceeds $12.50 per share for 20 days within any 30 consecutive trading days during the two-year period ending on November 12, 2023, and (ii) the remainder of which shall be released from escrow in the event the issuer's stock price equals or exceeds $15.00 per share for any 20 trading days within any 30-day trading period during the three-year period ending November 12, 2024. Notwithstanding the forgoing, all shares shall be released from escrow in the event of a qualifying change of control.

F4 · derivative.exercise_price: Represents shares of Common Equivalent Preferred Stock held in escrow, (i) 50% of which shall be released from escrow in the event the issuer's stock price equals or exceeds $12.50 per share for 20 days within any 30 consecutive trading days during the two-year period ending on November 12, 2023, and (ii) the remainder of which shall be released from escrow in the event the issuer's stock price equals or exceeds $15.00 per share for any 20 trading days within any 30-day trading period during the three-year period ending November 12, 2024. Notwithstanding the forgoing, all shares shall be released from escrow in the event of a qualifying change of control.

F1 · kind: Represents securities received in distributions to LLC members, on a pro rata basis for no consideration, in exempt transactions under Rule 16a-9.

F1 · price: Represents securities received in distributions to LLC members, on a pro rata basis for no consideration, in exempt transactions under Rule 16a-9.

F4 · derivative.exercise_date: Represents shares of Common Equivalent Preferred Stock held in escrow, (i) 50% of which shall be released from escrow in the event the issuer's stock price equals or exceeds $12.50 per share for 20 days within any 30 consecutive trading days during the two-year period ending on November 12, 2023, and (ii) the remainder of which shall be released from escrow in the event the issuer's stock price equals or exceeds $15.00 per share for any 20 trading days within any 30-day trading period during the three-year period ending November 12, 2024. Notwithstanding the forgoing, all shares shall be released from escrow in the event of a qualifying change of control.

F4 · derivative.expiration_date: Represents shares of Common Equivalent Preferred Stock held in escrow, (i) 50% of which shall be released from escrow in the event the issuer's stock price equals or exceeds $12.50 per share for 20 days within any 30 consecutive trading days during the two-year period ending on November 12, 2023, and (ii) the remainder of which shall be released from escrow in the event the issuer's stock price equals or exceeds $15.00 per share for any 20 trading days within any 30-day trading period during the three-year period ending November 12, 2024. Notwithstanding the forgoing, all shares shall be released from escrow in the event of a qualifying change of control.

SEC source: 0001628280-22-026163 · wf-form4_166517567146567.xml · derivative · entry 3

BARASCH RICHARD A · CIK 0001076341 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,595

Underlying: Common stock · 159,500 shares

Expires not disclosed

F3 · security: Each share of Series A Common Stock Equivalent Convertible Preferred Stock ("Common Equivalent Preferred Stock") is convertible into 100 shares of common stock (subject to adjustment) at any time and from time to time at the election of the holder thereof. The Common Equivalent Preferred Stock has no expiration date. The terms of the Common Equivalent Preferred Stock restrict the conversion of such shares to the extent that, upon such conversion, the number of shares of Class A Common Stock then beneficially owned by the holder and its affiliates and any other person or entities with which such holder would constitute a Section 13(d) "group" would exceed 4.9% of the total number of shares of Class A Common Stock then outstanding.

F3 · derivative.exercise_price: Each share of Series A Common Stock Equivalent Convertible Preferred Stock ("Common Equivalent Preferred Stock") is convertible into 100 shares of common stock (subject to adjustment) at any time and from time to time at the election of the holder thereof. The Common Equivalent Preferred Stock has no expiration date. The terms of the Common Equivalent Preferred Stock restrict the conversion of such shares to the extent that, upon such conversion, the number of shares of Class A Common Stock then beneficially owned by the holder and its affiliates and any other person or entities with which such holder would constitute a Section 13(d) "group" would exceed 4.9% of the total number of shares of Class A Common Stock then outstanding.

F1 · kind: Represents securities received in distributions to LLC members, on a pro rata basis for no consideration, in exempt transactions under Rule 16a-9.

F1 · price: Represents securities received in distributions to LLC members, on a pro rata basis for no consideration, in exempt transactions under Rule 16a-9.

F3 · derivative.exercise_date: Each share of Series A Common Stock Equivalent Convertible Preferred Stock ("Common Equivalent Preferred Stock") is convertible into 100 shares of common stock (subject to adjustment) at any time and from time to time at the election of the holder thereof. The Common Equivalent Preferred Stock has no expiration date. The terms of the Common Equivalent Preferred Stock restrict the conversion of such shares to the extent that, upon such conversion, the number of shares of Class A Common Stock then beneficially owned by the holder and its affiliates and any other person or entities with which such holder would constitute a Section 13(d) "group" would exceed 4.9% of the total number of shares of Class A Common Stock then outstanding.

F3 · derivative.expiration_date: Each share of Series A Common Stock Equivalent Convertible Preferred Stock ("Common Equivalent Preferred Stock") is convertible into 100 shares of common stock (subject to adjustment) at any time and from time to time at the election of the holder thereof. The Common Equivalent Preferred Stock has no expiration date. The terms of the Common Equivalent Preferred Stock restrict the conversion of such shares to the extent that, upon such conversion, the number of shares of Class A Common Stock then beneficially owned by the holder and its affiliates and any other person or entities with which such holder would constitute a Section 13(d) "group" would exceed 4.9% of the total number of shares of Class A Common Stock then outstanding.

SEC source: 0001628280-22-026163 · wf-form4_166517567146567.xml · nonDerivative · entry 2

BARASCH RICHARD A · CIK 0001076341 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Family Trust

Disclosed balance after: 8

F1 · kind: Represents securities received in distributions to LLC members, on a pro rata basis for no consideration, in exempt transactions under Rule 16a-9.

F1 · price: Represents securities received in distributions to LLC members, on a pro rata basis for no consideration, in exempt transactions under Rule 16a-9.

F2 · ownership.nature: Securities held by the Helen Barasch Family Trust #1 (the "Trust"), of which the reporting person is the investment manager and has voting and dispositive power over the securities held by the Trust, but disclaims beneficial ownership of these shares except to any pecuniary interest therein.

SEC source: 0001628280-22-026163 · wf-form4_166517567146567.xml · nonDerivative · entry 1

BARASCH RICHARD A · CIK 0001076341 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 142,019

F1 · kind: Represents securities received in distributions to LLC members, on a pro rata basis for no consideration, in exempt transactions under Rule 16a-9.

F1 · price: Represents securities received in distributions to LLC members, on a pro rata basis for no consideration, in exempt transactions under Rule 16a-9.

SEC source: 0000899243-22-033327 · doc4.xml · nonDerivative · entry 1

Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner

Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner

TOI HC I, LLC · CIK 0001892154 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 14,575,313

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.51 to $4.85, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.

F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein.

SEC source: 0000899243-22-032851 · doc4.xml · nonDerivative · entry 3

Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner

Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner

TOI HC I, LLC · CIK 0001892154 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 14,589,373

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.67 to $5.05, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.

F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein.

SEC source: 0000899243-22-032851 · doc4.xml · nonDerivative · entry 2

Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner

Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner

TOI HC I, LLC · CIK 0001892154 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 14,612,820

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.47 to $4.89, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein.

SEC source: 0000899243-22-032851 · doc4.xml · nonDerivative · entry 1

Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner

Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner

TOI HC I, LLC · CIK 0001892154 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 14,629,585

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.45 to $4.78, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.

F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein.

SEC source: 0000899243-22-032266 · doc4.xml · nonDerivative · entry 3

Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner

Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner

TOI HC I, LLC · CIK 0001892154 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 14,640,585

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.35 to $4.74, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.

F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein.

SEC source: 0000899243-22-032266 · doc4.xml · nonDerivative · entry 2

Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner

Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner

TOI HC I, LLC · CIK 0001892154 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 14,661,585

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.49 to $4.85, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein.

SEC source: 0000899243-22-032266 · doc4.xml · nonDerivative · entry 1

Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner

Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner

TOI HC I, LLC · CIK 0001892154 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 14,674,227

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.45 to $4.84, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.

F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein.

SEC source: 0000899243-22-032050 · doc4.xml · nonDerivative · entry 3

Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner

Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner

TOI HC I, LLC · CIK 0001892154 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 14,688,301

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.19 to $4.78, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.

F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein.

SEC source: 0000899243-22-032050 · doc4.xml · nonDerivative · entry 2

Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner

Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner

TOI HC I, LLC · CIK 0001892154 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 14,695,454

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.02 to $4.30, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein.

SEC source: 0000899243-22-032050 · doc4.xml · nonDerivative · entry 1

Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner

Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner

TOI HC I, LLC · CIK 0001892154 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 14,700,829

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.14 to $4.39, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.

F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein.

SEC source: 0000899243-22-031553 · doc4.xml · nonDerivative · entry 3

Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner

Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner

TOI HC I, LLC · CIK 0001892154 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 14,713,915

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.01 to $4.51, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.

F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein.

SEC source: 0000899243-22-031553 · doc4.xml · nonDerivative · entry 2

Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner

Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner

TOI HC I, LLC · CIK 0001892154 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 14,733,544

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.18 to $4.77, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein.

SEC source: 0000899243-22-031553 · doc4.xml · nonDerivative · entry 1

Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner

Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner

TOI HC I, LLC · CIK 0001892154 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 14,933,544

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.29 to $4.90, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.

F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein.

SEC source: 0000899243-22-031089 · doc4.xml · nonDerivative · entry 3

Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner

Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner

TOI HC I, LLC · CIK 0001892154 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 15,002,044

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.86 to $5.30, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.

F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein.

SEC source: 0000899243-22-031089 · doc4.xml · nonDerivative · entry 2

Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner

Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner

TOI HC I, LLC · CIK 0001892154 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 15,039,829

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.09 to $5.47, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein.

SEC source: 0000899243-22-031089 · doc4.xml · nonDerivative · entry 1

Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner

Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner

TOI HC I, LLC · CIK 0001892154 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 15,092,329

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.12 to $5.88, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.

F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein.

SEC source: 0000899243-22-030763 · doc4.xml · nonDerivative · entry 3

Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner

Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner

TOI HC I, LLC · CIK 0001892154 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 15,130,329

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.70 to $5.96, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.

F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein.

SEC source: 0000899243-22-030763 · doc4.xml · nonDerivative · entry 2

Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner

Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner

TOI HC I, LLC · CIK 0001892154 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 15,149,229

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.77 to $6.17, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein.

SEC source: 0000899243-22-030763 · doc4.xml · nonDerivative · entry 1

Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner

Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner

TOI HC I, LLC · CIK 0001892154 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 15,172,729

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.62 to $6.18, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.

F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein.

SEC source: 0000899243-22-030551 · doc4.xml · nonDerivative · entry 3

Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner

Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner

TOI HC I, LLC · CIK 0001892154 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 15,217,729

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.65 to $6.27, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.

F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein.

SEC source: 0000899243-22-030551 · doc4.xml · nonDerivative · entry 2

Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner

Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner

TOI HC I, LLC · CIK 0001892154 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 15,301,929

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.91 to $6.21, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein.

SEC source: 0000899243-22-030551 · doc4.xml · nonDerivative · entry 1

Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner

Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner

TOI HC I, LLC · CIK 0001892154 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 15,343,712

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.00 to $6.38, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.

F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein.

SEC source: 0000899243-22-030146 · doc4.xml · nonDerivative · entry 3

Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner

Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner

TOI HC I, LLC · CIK 0001892154 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 15,375,212

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.09 to $6.51, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.

F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein.

SEC source: 0000899243-22-030146 · doc4.xml · nonDerivative · entry 2

Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner

Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner

TOI HC I, LLC · CIK 0001892154 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 15,400,212

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.92 to $6.51, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein.

SEC source: 0000899243-22-030146 · doc4.xml · nonDerivative · entry 1

Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner

Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner

TOI HC I, LLC · CIK 0001892154 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 15,438,712

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.91 to $6.32, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.

F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein.

SEC source: 0000899243-22-029900 · doc4.xml · nonDerivative · entry 3

Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner

Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner

TOI HC I, LLC · CIK 0001892154 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 15,453,712

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.85 to $6.27, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.

F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein.

SEC source: 0000899243-22-029900 · doc4.xml · nonDerivative · entry 2

Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner

Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner

TOI HC I, LLC · CIK 0001892154 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 15,493,712

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.00 to $6.40, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein.

SEC source: 0000899243-22-029900 · doc4.xml · nonDerivative · entry 1

Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner

Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner

TOI HC I, LLC · CIK 0001892154 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 15,497,237

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.25 to $6.68, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.

F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein.

SEC source: 0000899243-22-029569 · doc4.xml · nonDerivative · entry 3

Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner

Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner

TOI HC I, LLC · CIK 0001892154 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 15,518,321

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.35 to $6.69, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.

F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein.

SEC source: 0000899243-22-029569 · doc4.xml · nonDerivative · entry 2

Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner

Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner

TOI HC I, LLC · CIK 0001892154 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 15,566,421

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.31 to $6.66, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein.

SEC source: 0000899243-22-029569 · doc4.xml · nonDerivative · entry 1

Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner

Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner

TOI HC I, LLC · CIK 0001892154 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 15,601,921

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.67 to $6.99, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.

F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein.

SEC source: 0000899243-22-028883 · doc4.xml · nonDerivative · entry 3

Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner

Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner

TOI HC I, LLC · CIK 0001892154 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 15,612,794

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.06 to $6.62, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.

F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein.

SEC source: 0000899243-22-028883 · doc4.xml · nonDerivative · entry 2

Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner

Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner

TOI HC I, LLC · CIK 0001892154 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 15,621,231

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.00 to $6.50, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein.

SEC source: 0000899243-22-028883 · doc4.xml · nonDerivative · entry 1

Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner

Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner

TOI HC I, LLC · CIK 0001892154 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 15,637,894

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.50 to $7.02, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.

F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein.

SEC source: 0001437749-22-015003 · rdgdoc.xml · derivative · entry 1

Agajanian Richy · CIK 0001895577 · 10% owner

Jimmy Holdings, Inc. · CIK 0001892174 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 296,075

Underlying: Class A Common Stock · 300,000 shares

Expires 2028-09-18

F1 · derivative.exercise_date: These stock options were received by Dr. Agajanian's spouse on November 12, 2021 in connection with a business combination. As of that date, 459,475 of the options were vested and 136,600 remained subject to vesting at the rate of 12,418 options each month, subject to Dr. Agajanian's spouse's continued employment with the issuer.

F1 · balance_after: These stock options were received by Dr. Agajanian's spouse on November 12, 2021 in connection with a business combination. As of that date, 459,475 of the options were vested and 136,600 remained subject to vesting at the rate of 12,418 options each month, subject to Dr. Agajanian's spouse's continued employment with the issuer.

F2 · ownership.nature: Held by Dr. Agajanian's spouse. The reporting persons disclaim beneficial ownership of these securities.

SEC source: 0001628280-22-014963 · wf-form4_165300021470983.xml · derivative · entry 2

Shah Mihir · CIK 0001676960 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 163,039

Underlying: Class A Common Stock · 163,039 shares

Expires 2032-05-19

F2 · derivative.exercise_date: The stock options vest in four equal annual installments on each of the first four anniversaries of the Vesting Commencement Date, with all stock options becoming vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates.

SEC source: 0001628280-22-014963 · wf-form4_165300021470983.xml · nonDerivative · entry 1

Shah Mihir · CIK 0001676960 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,121

F1 · shares: Represents restricted stock units ("RSUs") that vest in four equal annual installments on each of the first four anniversaries of May 19, 2022 (the "Vesting Commencement Date"), with all RSUs becoming vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates.

SEC source: 0001437749-22-012393 · rdgdoc.xml · nonDerivative · entry 2

Agajanian Richy · CIK 0001895577 · 10% owner

Jimmy Holdings, Inc. · CIK 0001892174 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 253,436

F2 · ownership.nature: Held by Agajanian Holdings LLC. The membership interests of Agajanian Holdings LLC are held by three trusts each of which Richy Agajanian is a trustee or co-trustee and in such capacity has or shares voting and dispositive authority. The reporting persons disclaim beneficial ownership of these securities except to extent of Richy Agajanian's pecuniary interest as a result of being a beneficiary of one or more of the trusts.

SEC source: 0001437749-22-012393 · rdgdoc.xml · nonDerivative · entry 1

Agajanian Richy · CIK 0001895577 · 10% owner

Jimmy Holdings, Inc. · CIK 0001892174 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 6,295,688

F1 · ownership.nature: Held directly by Jimmy Holdings, Inc. and indirectly by Richy Agajanian, the sole holder of all of the outstanding capital stock of Jimmy Holdings, Inc.

SEC source: 0001628280-22-007094 · wf-form4_164807845002324.xml · nonDerivative · entry 1

BARASCH RICHARD A · CIK 0001076341 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 142,018

F1 · shares: Represents restricted stock units that vest in full on November 12, 2022, subject to continued service with the Company through such vesting date.

F1 · price: Represents restricted stock units that vest in full on November 12, 2022, subject to continued service with the Company through such vesting date.

SEC source: 0001628280-22-007103 · wf-form4_164807863846129.xml · derivative · entry 2

Dalgleish Scott · CIK 0001891053 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,062

Underlying: Common stock · 26,062 shares

Expires 2032-03-21

F2 · derivative.exercise_date: The stock options vest as to 1/3rd of the options granted on the second anniversary of the Vesting Commencement Date, with the remaining options vesting in four equal annual installments beginning on the third anniversary of the Vesting Commencement Date, with all options becoming vested on the sixth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates.

SEC source: 0001628280-22-007103 · wf-form4_164807863846129.xml · nonDerivative · entry 1

Dalgleish Scott · CIK 0001891053 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 151,008

F1 · shares: Represents RSUs with 1/3rd of the RSUs vesting on the second anniversary of November 12, 2021 ("the Vesting Commencement Date"), with the remaining RSUs vesting in four equal annual installments beginning on the third anniversary of the Vesting Commencement Date, with all RSUs becoming vested on the sixth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates.

F1 · price: Represents RSUs with 1/3rd of the RSUs vesting on the second anniversary of November 12, 2021 ("the Vesting Commencement Date"), with the remaining RSUs vesting in four equal annual installments beginning on the third anniversary of the Vesting Commencement Date, with all RSUs becoming vested on the sixth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates.

SEC source: 0001628280-22-007102 · wf-form4_164807861674913.xml · nonDerivative · entry 2

SARIN RAVI YANG · CIK 0001555959 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,191